Novo Nordisk receives FDA warning over safety reporting delays but secures a new sales channel for Ozempic and Wegovy via Hims & Hers, as GLP-1 drug safety faces scrutiny.
Danish pharmaceutical giant Novo Nordisk finds itself navigating a complex landscape of both opportunity and regulatory scrutiny. Recent developments present a mixed picture for the company, whose shares have been trading well below their annual peak for several months.
FDA Issues Formal Warning Over Reporting Delays
The U.S. Food and Drug Administration (FDA) has issued a formal warning letter to Novo Nordisk following an inspection at its Plainsboro, New Jersey facility conducted from January to February 2025. The agency cited “serious violations,” alleging the company failed to report adverse events within the mandated 15-day timeframe.
Specifically, the FDA identified delayed reports concerning two patient deaths, a suicide, and a stroke linked to semaglutid-based products. In some instances, these crucial safety reports were allegedly submitted more than 800 days late. While Novo Nordisk has stated it is working to address these systemic deficiencies and does not anticipate an impact on production capacity, the warning adds significant pressure.
Patent Dispute Resolution Opens New Sales Channel
In a contrasting positive development, Novo Nordisk has resolved its patent litigation with the telemedicine platform Hims & Hers Health. As part of the settlement, Hims & Hers will begin directly offering the branded drugs Ozempic and Wegovy through its platform starting in late March 2026.
This agreement marks a strategic shift for the platform, which had previously offered generic versions of semaglutid. For Novo Nordisk, it establishes an additional official distribution channel and eliminates an ongoing legal dispute. Analysts from Citigroup and Bank of America subsequently updated their assessments of Hims & Hers Health, noting the removal of associated litigation risk.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Broader Safety Concerns for GLP-1 Drug Class
Regulatory attention is not confined to the United States. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has also reported two fatalities potentially connected to GLP-1 medications. Medical professionals are further raising alarms about possible risks of kidney damage and severe gastrointestinal issues with long-term use of these drugs.
Amid this challenging environment, Novo Nordisk has made a commitment to global health equity, allocating $7.9 million to the WHO Foundation. This funding is intended to support healthcare systems in low-income countries for the treatment of obesity and diabetes.
Investment Outlook Remains Cautious
Novo Nordisk’s stock has shed more than half its value over the past twelve months and is currently hovering just above its 52-week low. The path forward appears contingent on two key factors: the company’s ability to convincingly implement its corrective action plan with the FDA, and whether the ongoing safety debate surrounding GLP-1 medications further erodes confidence in the entire product portfolio.
Ad
Novo Nordisk Stock: New Analysis – 12 March
Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Novo Nordisk analysis…
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt anmelden.
Für immer kostenlos